EXPERIMENTAL DRUG DEVELOPMENT CENTRE EDDC

Experimental Drug Development Centre (EDDC) is neither a factory nor a trading company. It is a research and development center.

Company Introduction:

Experimental Drug Development Centre (EDDC) is Singapore's national platform for drug discovery and development. It is part of the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector agency that spearheads economic-oriented research.

EDDC's primary mission is to translate scientific discoveries into innovative therapies that address unmet medical needs. The center focuses on early-stage drug discovery and development, from target identification and validation through lead optimization and preclinical development. It aims to build a robust pipeline of novel drug candidates for various diseases, including oncology, infectious diseases, and metabolic disorders.

The center leverages state-of-the-art facilities, advanced technologies, and a multidisciplinary team of scientists with expertise in chemistry, biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). EDDC collaborates extensively with academic institutions, pharmaceutical companies, biotechnology firms, and clinical partners both locally and internationally to accelerate the development of new drugs.

By fostering a collaborative ecosystem and driving cutting-edge research, EDDC plays a crucial role in strengthening Singapore's biomedical sciences industry and contributing to global healthcare innovation. Its ultimate goal is to bring new therapeutic solutions to patients worldwide.

The Experimental Drug Development Centre (EDDC) in Singapore, a national platform under A*STAR, does not produce or sell commercial pharmaceutical products in the traditional sense of a drug company. Instead, its primary output and focus are on the discovery and development of early-stage drug candidates and enabling technologies, which are then typically licensed to pharmaceutical companies or form the basis for spin-off companies for further clinical development and commercialization.

EDDC's core outputs include:

Drug Candidates

These are novel therapeutic molecules, such as small molecules or biologics, that have been discovered, optimized, and advanced through preclinical development. The goal is to progress these candidates to a stage where they are ready for clinical trials (Phase 1 or Phase 2).

Therapeutic Targets

Identification and validation of new biological targets that play a critical role in various diseases, which can then be exploited for drug discovery.

Enabling Technologies and Platforms

Development of innovative tools, assays, and scientific platforms that enhance and accelerate the drug discovery process. Examples include advanced screening capabilities, medicinal chemistry expertise, and in vivo model development.

Diagnostic Tools and Biomarkers

Research may lead to the identification of biomarkers or the development of diagnostic assays that assist in disease detection, prognosis, or patient selection for clinical trials.

Intellectual Property

Creation of patents and other forms of intellectual property to protect their scientific discoveries and technological advancements.

Spin-off Companies

EDDC's programs and drug assets have led to the formation of new biotechnology companies that take forward the development and commercialization of specific drug candidates.

EDDC primarily focuses its research efforts on therapeutic areas such as oncology (cancer), infectious diseases, metabolic disorders, and inflammatory diseases. Its "products" are essentially pre-clinical and early-clinical stage drug assets and the foundational scientific and technological breakthroughs that pave the way for future medicines.